ArticleTranslational and clinical pharmacology2026
Pharmacokinetics and safety of nafamostat and its metabolites following single- and multiple-dose oral administration of nafamostat mesylate in healthy male participants.
Article in Translational and clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nafamostat mesylate, a serine protease inhibitor, is a potential antiviral agent that inhibits the intracellular entry of severe acute respiratory syndrome coronavirus-2. An oral formulation is under development to improve patient compliance over the existing intravenous formulation. This study evaluated the pharmacokinetics (PKs) and safety of oral nafamostat mesylate following single and multiple doses in healthy male participants. An open-label, single-dose and multiple ascending dose (MAD) study was conducted. In the single-dose study, 8 participants were administered 200 mg of nafamostat mesylate. In the MAD study, 8 participants in each dose group received nafamostat mesylate 100, 200, or 400 mg every 6 hours (QID) for 7 days. PKs were assessed for nafamostat in the single-dose study, and for nafamostat, 6-amidino-2-naphthol (AN) and 4-guanidinobenzoic acid (GBA) in the MAD study. The safety and tolerability were evaluated throughout the study. The median time to maximum concentration at steady state was 0.50-0.88 hours for nafamostat, 1.75-2.00 hours for AN, and 2.50-3.50 hours for GBA. Terminal elimination half-life ranged 0.61-3.84, 21.24-31.44, and 8.28-14.70 hours respectively. The accumulation ratio of nafamostat was 23.86 at 400 mg QID, with no accumulation at 100 and 200 mg QID. The mean accumulation ratios were 7.43-13.73 for AN and 1.84-2.11 for GBA. Nafamostat exposure showed a more than dose-proportional increase, whereas metabolites exposures were dose-proportional. No serious adverse events were reported. Multiple doses of oral nafamostat mesylate were well-tolerated up to 400 mg QID in healthy male participants. Trial Registration: Clinical Research Information Service Identifier: KCT0005647.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.